Crossmark

New Trials in Lupus and where Are we Going

Crossref DOI link: https://doi.org/10.1007/s11926-018-0745-1

Published Online: 2018-05-03

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Thanou, Aikaterini

Merrill, Joan T.
License Information

Text and Data Mining valid from 2018-05-03
More Information

Article History

First Online: 3 May 2018

Compliance with Ethical Standards

:

: Dr. Merrill reports grants and personal fees from Bristol Myers Squibb, grants and personal fees from Glaxo Smith Kline, personal fees from UCB, personal fees from Amgen, personal fees from Celgene, personal fees from EMD Serono, personal fees from MedImmune, personal fees from Lilly, personal fees from Jannsen, personal fees from Xencor, personal fees from Biogen IDEC, personal fees from Neovacs, personal fees from Anthera, personal fees from RemeGen, and personal fees from ImmunPharma during the conduct of the study.Dr. Thanou has received research grants from Bristol Myers Squibb and Glaxo Smith Kline.

: This article does not contain any studies with human or animal subjects performed by any of the authors.